150 related articles for article (PubMed ID: 7489999)
1. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.
Dusheiko GM; Roberts JA
Hepatology; 1995 Dec; 22(6):1863-73. PubMed ID: 7489999
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
Aggarwal R; Ghoshal UC; Naik SR
Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
[TBL] [Abstract][Full Text] [Related]
3. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C.
Shiell A; Briggs A; Farrell GC
Med J Aust; 1994 Mar; 160(5):268-72. PubMed ID: 8107627
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness analysis of the treatment of chronic hepatitis C].
Joliot E; Vanlemmens C; Kerleau M; Le Gales C; Woronoff-Lemsi MC; Flori YA; Seror V; Hrusovsky S; Monnet E; Bresson-Hadni S; Miguet JP
Gastroenterol Clin Biol; 1996; 20(11):958-67. PubMed ID: 9119185
[TBL] [Abstract][Full Text] [Related]
5. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
Sheerin IG; Green FT; Sellman JD
Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.
Brooks EA; Lacey LF; Payne SL; Miller DW
Am J Manag Care; 2001 Jul; 7(7):677-82. PubMed ID: 11464426
[TBL] [Abstract][Full Text] [Related]
7. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
8. [Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha].
Buti M; Casado MA; Fosbrook L; Esteban R
Gastroenterol Hepatol; 1998 Apr; 21(4):161-8. PubMed ID: 9633175
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of interferon in chronic active hepatitis C.
Turnbull C; Sugano D
Med J Aust; 1994 Jul; 161(2):169; author reply 170. PubMed ID: 8028544
[No Abstract] [Full Text] [Related]
10. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?
Saab S; Ly D; Han SB; Lin RK; Rojter SE; Ghobrial RM; Busuttil RW
Liver Transpl; 2002 May; 8(5):449-57. PubMed ID: 12004345
[TBL] [Abstract][Full Text] [Related]
11. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
Kumar R; Singla V; Kacharya Sk
Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
[TBL] [Abstract][Full Text] [Related]
12. Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B.
Louis-Jacques O; Olson AD
J Pediatr Gastroenterol Nutr; 1997 Jan; 24(1):25-32. PubMed ID: 9093982
[TBL] [Abstract][Full Text] [Related]
13. An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus.
Garcia de Ancos JL; Roberts JA; Dusheiko GM
J Hepatol; 1990; 11 Suppl 1():S11-8. PubMed ID: 2127784
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.
Wong JB; Koff RS; Tinè F; Pauker SG
Ann Intern Med; 1995 May; 122(9):664-75. PubMed ID: 7702228
[TBL] [Abstract][Full Text] [Related]
15. The clinical application of the interferons: a review. NSW Therapeutic Assessment Group.
Stuart-Harris RC; Lauchlan R; Day R
Med J Aust; 1992 Jun; 156(12):869-72. PubMed ID: 1376397
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness analysis of treatment of chronic hepatitis B with interferon in Chinese city].
Lin X; Ding D; Zhang P
Zhonghua Gan Zang Bing Za Zhi; 1999 Jun; 7(2):84-7. PubMed ID: 10488414
[TBL] [Abstract][Full Text] [Related]
17. Review of cost-effectiveness studies of pegylated therapies for hepatitis C.
Shaya FT; Klaskala W; Mullins CD
Expert Rev Pharmacoecon Outcomes Res; 2005 Jun; 5(3):339-51. PubMed ID: 19807603
[TBL] [Abstract][Full Text] [Related]
18. [Economic evaluation of health care program for hepatitis C virus antibody screening].
Ishizuka M
Nihon Koshu Eisei Zasshi; 1999 Jun; 46(6):447-65. PubMed ID: 10513088
[TBL] [Abstract][Full Text] [Related]
19. [Costs of guideline-based treatment of hepatitis B patients in Germany].
Stahmeyer JT; Becker H; Heidelberger S; Wiebner B; Deterding K; Cornberg M; Manns MP; Krauth C; Wedemeyer H
Z Gastroenterol; 2012 Aug; 50(8):745-52. PubMed ID: 22895902
[TBL] [Abstract][Full Text] [Related]
20. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?
Leal P; Stein K; Rosenberg W
J Med Screen; 1999; 6(3):124-31. PubMed ID: 10572842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
